Portfolio / Alveron

Alveron.gif


Alveron Pharma is developing a unique coagulation platform technology with the world’s first cyclodextrin-based anticoagulant reversal drug.

Alveron Pharma's proprietary cyclodextrin-based compounds accelerate, but not initiate, coagulation via a unique mechanism. These compounds can therefore be used as systemic anti-bleeding agents, and our lead program is focused on developing a truly universal anticoagulant reversal agent.

Website

Company: aLVERON

Fund: II

Status: Active

Team member:

Michel Briejer

05.jpg
 

Technology:

Therapeutics

logo therapeutics.jpg